CeriBell (NASDAQ:CBLL – Get Free Report) had its target price boosted by equities research analysts at BTIG Research from $28.00 to $30.00 in a research report issued on Tuesday, Marketbeat reports. The brokerage currently has a “buy” rating on the stock. BTIG Research’s price objective would indicate a potential upside of 22.95% from the stock’s current price.
Several other research analysts have also recently issued reports on CBLL. Weiss Ratings raised CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday. Canaccord Genuity Group lifted their price objective on shares of CeriBell from $25.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, CeriBell presently has a consensus rating of “Moderate Buy” and an average price target of $22.40.
CeriBell Stock Performance
CeriBell (NASDAQ:CBLL – Get Free Report) last posted its earnings results on Monday, August 10th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.04). The business had revenue of $28.10 million during the quarter, compared to analyst estimates of $27.28 million. CeriBell had a negative net margin of 64.73% and a negative return on equity of 44.85%. On average, equities research analysts forecast that CeriBell will post -1.96 EPS for the current year.
Insider Buying and Selling at CeriBell
In related news, major shareholder Tpg Gp A, Llc sold 202,368 shares of the business’s stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $20.12, for a total transaction of $4,071,644.16. Following the sale, the insider owned 3,765,054 shares of the company’s stock, valued at $75,752,886.48. The trade was a 5.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Xingjuan Chao sold 39,000 shares of the company’s stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $18.33, for a total value of $714,870.00. Following the completion of the sale, the chief executive officer owned 816,317 shares of the company’s stock, valued at $14,963,090.61. This trade represents a 4.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 313,780 shares of company stock valued at $6,241,749. 17.70% of the stock is currently owned by company insiders.
Institutional Trading of CeriBell
Institutional investors have recently modified their holdings of the company. Russell Investments Group Ltd. boosted its stake in CeriBell by 41.4% during the fourth quarter. Russell Investments Group Ltd. now owns 2,918 shares of the company’s stock valued at $64,000 after buying an additional 854 shares in the last quarter. Sei Investments Co. raised its position in CeriBell by 2.3% in the first quarter. Sei Investments Co. now owns 50,360 shares of the company’s stock worth $923,000 after acquiring an additional 1,125 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its holdings in CeriBell by 3,971.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock valued at $28,000 after acquiring an additional 1,231 shares during the last quarter. Deutsche Bank AG boosted its position in shares of CeriBell by 1.7% during the 4th quarter. Deutsche Bank AG now owns 85,182 shares of the company’s stock valued at $1,868,000 after purchasing an additional 1,393 shares in the last quarter. Finally, Strs Ohio bought a new position in shares of CeriBell during the 1st quarter valued at about $27,000.
About CeriBell
CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.
The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.
Read More
- Five stocks we like better than CeriBell
- 3 Infrastructure Stocks Built Around the Backbone of the Economy
- Moonshot to Money: Intuitive Machines Lands $600M Defense Win
- Commodities Are Booming, But These 3 ETFs Tell Different Stories
- 3 Active ETFs Making Big Moves in August
Receive News & Ratings for CeriBell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CeriBell and related companies with MarketBeat.com's FREE daily email newsletter.
